Ann: Removal from Official List, page-9

I wont mention the name, but NXR was brought to my attention by a fellow holder of ACL. Following a failure of that companies ph3 trial he/she posted what a contrasting example NXR was to ACL. Well managed, focused, informed the market, great directors, fantastic product close to commercialisation, cough, I think I just passed a fur ball, cough. I was probably one of the last people on the planet to buy shares in Nemex, in that tiny window between the AGM 3 years ago and the suspension.

What a FLICK UP.